Parathyroid Hormone
drugOn this page
Also known as ALX-111Hormona paratiroideaHormone parathyroideNatparNatparaNPSP-558NPSP558Parathormone (human recombinant)ParathormonumParathyroidParathyroid hormone (rdna)Preotact
Summary
Parathyroid Hormone (CHEMBL2108078) is an approved protein (ATC H05AA03); indicated across 6 conditions including postmenopausal osteoporosis and hypoparathyroidism.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: H05AA03
- Indications: 6 conditions
- Clinical trials: 36
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108078 |
| Name | Parathyroid Hormone |
| Type | Protein |
| Max phase | 4 |
| ATC | H05AA03 |
Also known as: ALX-111, Hormona paratiroidea, Hormone parathyroide, Natpar, Natpara, NPSP-558, NPSP558, Parathormone (human recombinant), Parathormonum, Parathyroid, Parathyroid hormone, Parathyroid hormone (rdna)
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| postmenopausal osteoporosis | 4 | MONDO:0008159 | EFO:0003854 |
| hypoparathyroidism | 4 | MONDO:0001220 | EFO:0009451 |
| osteoporosis | 3 | MONDO:0005298 | EFO:0003882 |
| psoriasis | 1 | MONDO:0005083 | EFO:0000676 |
| hyperparathyroidism | 0 | MONDO:0001741 | EFO:0008506 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 36.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 12 |
| Not specified | 10 |
| PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00221299 | PHASE4 | COMPLETED | Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use |
| NCT00479037 | PHASE4 | COMPLETED | Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) |
| NCT02910466 | PHASE4 | COMPLETED | A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism |
| NCT00000427 | PHASE3 | COMPLETED | Effects of Parathyroid Hormone in Men With Osteoporosis |
| NCT00172081 | PHASE3 | COMPLETED | TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis |
| NCT00172120 | PHASE3 | COMPLETED | Open Label Extension |
| NCT00172133 | PHASE3 | COMPLETED | Open Label Extension Study of PREOS |
| NCT00683163 | PHASE2/PHASE3 | COMPLETED | PTH & Ibandronate Combination Study (PICS) |
| NCT00732615 | PHASE3 | COMPLETED | Use of NPSP558 in the Treatment of Hypoparathyroidism |
| NCT01199614 | PHASE3 | COMPLETED | HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism |
| NCT01268098 | PHASE3 | COMPLETED | Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY) |
| NCT01297309 | PHASE3 | COMPLETED | A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) |
| NCT01455181 | PHASE3 | COMPLETED | A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary |
| NCT01466829 | PHASE3 | COMPLETED | Treatment With PTH After Sternotomy in Cardiac Surgery Patients |
| NCT03364738 | PHASE3 | TERMINATED | Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism |
| NCT03878953 | PHASE3 | WITHDRAWN | A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism |
| NCT06961071 | PHASE1/PHASE2 | RECRUITING | Parathyroid Allotransplant for Treatment of Hypoparathyroidism |
| NCT00005006 | PHASE2 | COMPLETED | Parathyroid Hormone (PTH) With Alendronate for Osteoporosis |
| NCT00172107 | PHASE2 | COMPLETED | A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis |
| NCT00853723 | PHASE2 | COMPLETED | Comparison Study of PTHrP and PTH to Treat Osteoporosis |
| NCT03516773 | PHASE2 | COMPLETED | Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism |
| NCT01333267 | PHASE1 | WITHDRAWN | One Week Comparison Study of PTH and PTHrP Infusions |
| NCT02781844 | PHASE1 | COMPLETED | Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism |
| NCT03150108 | PHASE1 | COMPLETED | Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects |
| NCT05137730 | PHASE1 | COMPLETED | A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults |
| NCT00377312 | EARLY_PHASE1 | COMPLETED | 7 Day Continuous Parathyroid Hormone IV Infusion |
| NCT05114980 | Not specified | NOT_YET_RECRUITING | Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism |
| NCT06499246 | Not specified | RECRUITING | Parathyroid Allotransplant for Severe Refractory Hypoparathyroidism |
| NCT00501215 | Not specified | COMPLETED | Effect of Parathyroidectomy on Sleep |
| NCT01087619 | Not specified | COMPLETED | Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up |
| NCT02134483 | Not specified | COMPLETED | Parathyroid Allo-transplantation With a New Technique |
| NCT02227264 | Not specified | COMPLETED | Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions? |
| NCT02249780 | Not specified | COMPLETED | Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy |
| NCT03516747 | Not specified | WITHDRAWN | Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland |
| NCT03873675 | Not specified | COMPLETED | Parathyroid Hormone Kinetics During CRRT |
| NCT05275491 | Not specified | COMPLETED | Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).